Short answer
PTC THERAPEUTICS, INC. (PTCT) filed its fiscal 2025 10-K annual report with the SEC on Feb 19, 2026. It reported revenue of $1.7B (+114.5% year over year) and net income of $683M.
- Top risk flagged: Regulatory risk U.S. FDA withdrawal of Translarna NDA resubmission for nmDMD after negative feedback in January 2026
FY2025 key financial metrics · XBRL
- Revenue
- $1.7B
- +114.5% YoY
- Net income
- $683M
- +287.9% YoY
- Operating margin
- 50.1%
- +87.6 pp YoY
- EPS (diluted)
- $7.78
- +264.5% YoY
- ROE
- -332.5%
- −365.6 pp YoY
- Operating cash flow
- $711M
- +760.4% YoY
Source: XBRL data from the PTC THERAPEUTICS, INC. (PTCT) FY2025 10-K on SEC EDGAR. USD.
PTC THERAPEUTICS, INC. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: Development and commercialization of treatments for rare diseases, with focus on sepiapterin programs from Censa acquisition
- Strategic shift: Rights Satisfaction Agreement canceled contingent net sales payments, replaced with upfront $225.1M cash payment plus up to $500M milestone payments
- Notable quantitative metric: $152.5M paid in development/regulatory milestones for sepiapterin since acquisition, including $57.5M in 2025 alone
- Financial risk detail: Stressed need for substantial additional funding; reliance on equity, debt, collaborations, with potential dilution and restrictive covenants risks
Management Discussion & Analysis
- Revenue impact: upfront $1.0B from Novartis Agreement in Jan 2025, with potential $1.9B milestones, 40% US profits share, tiered double-digit royalties ex-US
- Operating cash flow $711.2M in 2025 vs $(107.7)M in 2024 and $(158.4)M in 2023, driven by Novartis upfront and clinical/commercial spend
- Investing cash flow used $862.0M in 2025, primarily for product rights acquisition, marketable securities, and fixed assets purchases
- Financing cash flow $331.1M in 2025 from Royalty Pharma fundings, option exercises, ESPP issuance, offset by contingent consideration and lease payments
- Forward risks: ongoing costs from commercialization, clinical trials, regulatory requirements; milestone and royalty payment obligations; dependence on market access and pricing; 2026 Convertible Notes interest $4.3M annually
Risk Factors
- Regulatory risk U.S. FDA withdrawal of Translarna NDA resubmission for nmDMD after negative feedback in January 2026
- Geopolitical exposure Sephience marketing approvals in U.S., EEA, Japan, Brazil with $111.2M 2025 net revenues, but country-specific pricing/licensing risks
- Operational risk Emflaza U.S. orphan drug exclusivity expired Feb 2024 leading to increased generic competition impacting revenue
- Competitive risk Emflaza facing generic competition post orphan drug exclusivity expiration, negatively affecting net product revenue
- Financial risk Revenue concentration: Translarna net revenues $235.3M and Emflaza $146.4M in 2025, key products with regulatory uncertainties
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.